The increase in price target by B of A Securities suggests a positive outlook on the value of Roivant Sciences, which could lead to increased investor confidence and a potential short-term rise in the stock price. However, the Neutral rating indicates that the analyst does not see significant momentum beyond the revised target, tempering the impact.